Cardiovascular development

Pelacarsen Lowered Lp(a) and Missed Its Cardiovascular Endpoint

Pelacarsen lowered Lp(a) in Phase 3 Lp(a)HORIZON. See what the neutral cardiovascular outcomes mean for Amgen, Lilly, and clinical trial teams.

By Lampgen Clinical Research

A magnifying lens rests on a stack of blank case-file documents. The Lampgen Clinical Insights cover asks, “What counts as an event?”
Editorial illustration of records assembled for endpoint review.
12.3% with pelacarsen12.1% with placebo
Participants who experienced a primary endpoint event in Phase 3 Lp(a)HORIZON over a median 4.7 years of follow-up. [1]

What the source reported

Pelacarsen substantially lowered lipoprotein(a), or Lp(a), in adults with established cardiovascular disease. The Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events compared with placebo. The November 7, 2026 readout at the American Heart Association Scientific Sessions gives sponsors a reason to require direct outcomes evidence when developing drugs that lower Lp(a). [1–3]

What Lp(a)HORIZON measured

The efficacy analysis included 8,322 adults with established cardiovascular disease and screening Lp(a) of at least 70 mg/dL. Participants received monthly injections of pelacarsen, an investigational antisense oligonucleotide that reduces Lp(a) production, or placebo alongside guideline-directed care. Median Lp(a) was 236 nmol/L at baseline. At 12 months it was 64.4 nmol/L in the pelacarsen group and 233.4 nmol/L in the placebo group. [1–3]

The primary endpoint measured time to cardiovascular death, nonfatal heart attack, nonfatal stroke, or urgent coronary revascularization requiring hospitalization. The hazard ratio was 1.02 (95% confidence interval 0.90–1.15, P = 0.76). Among participants with baseline Lp(a) of at least 90 mg/dL, 12.3% in each group had a primary endpoint event. Serious adverse events occurred in 37.3% on pelacarsen and 41.1% on placebo. Injection-site reactions were more frequent with pelacarsen. [1–3]

What comes next for Amgen and Lilly

Amgen’s olpasiran and Lilly’s lepodisiran use small interfering RNA to reduce Lp(a) production. Earlier trials showed large reductions in Lp(a) with both candidates. Their Phase 3 outcomes studies test clinical benefit separately. Amgen’s OCEAN(a)-Outcomes requires Lp(a) of at least 200 nmol/L and established atherosclerotic disease. Lilly’s ACCLAIM-Lp(a) uses at least 175 nmol/L and includes people with established disease as well as some at high risk of a first event. [4–7]

Eligibility thresholds describe who can enter a study. The baseline distribution describes who actually enrolled. HORIZON used a mass-based screening cutoff and reported a median baseline concentration of 236 nmol/L. A single conversion between mg/dL and nmol/L is unreliable because the size of the protein varies. When the next studies report, compare the enrolled populations, endpoint definitions, duration of lowering, and absolute event rates. Elevated Lp(a) remains a cardiovascular risk factor. [1, 4, 5, 8]

A parallel result from the ZEUS trial

At the same meeting, Novo Nordisk’s Phase 3 ZEUS trial reported that ziltivekimab lowered inflammatory markers, including high-sensitivity C-reactive protein. Cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 17.6% on ziltivekimab and 17.7% on placebo among adults with atherosclerotic disease, chronic kidney disease, and elevated inflammation. Together the two readouts show how much information a randomized clinical outcome can add after a drug has demonstrated a biological effect. [9, 10]

What this means for trial teams

Rehearse the outside-hospital handoff. Consider a hypothetical participant who is admitted to a hospital outside the research network. At startup, establish who requests the source records, what the adjudication charter requires, and who follows the case until it can be reviewed. The site reports the potential event, the CRA verifies that documentation gaps are addressed through the monitoring plan, and the adjudication committee applies the endpoint definition. [11]

Protect follow-up over time. Document who continues event follow-up after treatment ends, consistent with the protocol and participant consent. Review whether recruitment and follow-up differ by site, referral setting, sex, race, and ethnicity. Women accounted for 27% of HORIZON participants. A screening log linked to a follow-up report can show where access or retention needs closer review. [1, 11, 12]

Track one measure across sites. With Lampgen’s SIGNAL™ framework, review the time from site awareness of a potential event to submission of a complete packet. If overdue cases cluster, check where the handoff stalled, assign the fix to the team that can make it, and measure completion in the next review period. The same approach can support oncology trials when another institution documents a new therapy or vital status. [11, 13]

Sources

  1. Cho et al., primary Lp(a)HORIZON results, New England Journal of Medicine, November 7, 2026
  2. American Heart Association, Lp(a)HORIZON late-breaking science presentation and safety summary
  3. ClinicalTrials.gov, Lp(a)HORIZON, NCT04023552
  4. ClinicalTrials.gov, Amgen OCEAN(a)-Outcomes, NCT05581303
  5. Eli Lilly, ACCLAIM-Lp(a) study design and eligibility, NCT06292013
  6. O’Donoghue et al., Phase 2 OCEAN(a)-DOSE results for olpasiran, New England Journal of Medicine
  7. Nissen et al., Phase 2 ALPACA results for lepodisiran, New England Journal of Medicine
  8. Kronenberg et al., European Atherosclerosis Society consensus on Lp(a) and cardiovascular risk
  9. Ridker et al., primary ZEUS results, New England Journal of Medicine, November 7, 2026
  10. American Heart Association, ZEUS late-breaking science presentation
  11. FDA, ICH E6(R3) Good Clinical Practice final guidance
  12. Lampgen Clinical Insights, clinical trial participation burden and patient access
  13. Lampgen, a worked SIGNAL™ monitoring case

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?